Contents
|
Introduction |
3 |
|
Saudi Arabia |
5 |
|
The Pharmaceutical Market |
5 |
|
Health Services |
5 |
|
Overview |
8 |
|
Market Assessment |
10 |
|
Competitive Assessment |
13 |
|
Domestic Production |
14 |
|
Imports |
16 |
|
Market Access |
16 |
|
Best Market Opportunity |
18 |
|
Trade Fairs |
19 |
|
Primary Pharmaceutical Companies |
20 |
|
Recent Foreign Investments |
29 |
|
Regulations for the Registration of Generic Drugs |
30 |
|
Prevalent Medical Disorders |
32 |
|
County Investment – General Information |
36 |
|
Business Opportunities |
44 |
|
Key Contacts and Public Health Officials |
47 |
|
Kuwait |
50 |
|
The Pharmaceutical Market |
50 |
|
Market Assessment |
50 |
|
Competitive Assessment |
53 |
|
Market Access |
53 |
|
Best Market Prospects |
54 |
|
Primary Pharmaceutical Companies |
55 |
|
Country Investment – General Information |
57 |
|
Key Contacts and Public Health Officials |
61 |
|
The United Arab Emirates |
62 |
|
The Pharmaceutical Market |
62 |
|
Overview |
62 |
|
Market Access |
63 |
|
Best Market Opportunity |
64 |
|
Pharmaceutical Companies |
65 |
|
Foreign Business Ventures |
65 |
|
Prevalent Medical Disorders |
66 |
|
Country Investment – General Information |
66 |
|
Key Contacts |
68 |
|
The GCC and Unified Projects in the Gulf |
68 |
Table 1: Per Capita Pharmaceutical Market, 1991
|
Country |
Market ($) |
|
UAE |
65.2 |
|
Saudi Arabia |
55.7 |
|
Qatar |
38.8 |
|
Kuwait |
29.5 |
|
Bahrain |
28.2 |
|
Libya |
24.2 |
|
Oman |
22.1 |
|
Lebanon |
19.3 |
|
Turkey |
18.5 |
|
Jordan |
15.7 |
|
Iran |
13.9 |
|
Syria |
9.9 |
|
Egypt |
7.5 |
|
Yemen |
4.5 |
|
Iraq |
2.1 |
|
Total (Av) |
15.1 |
Table 2: Combined MoH/EB Purchases
|
Country |
$ Million |
% of Total |
|
Saudi Arabia |
171 |
57 |
|
Kuwait |
57 |
19 |
|
UAE |
32 |
11 |
|
Qatar |
20 |
7 |
|
Bahrain |
7 |
2 |
|
Jordan (MoH only) |
8 |
3 |
|
Oman (GCC only) |
5 |
2 |
|
Total |
300 |
100 |
